Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2023-01-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the fourth board of directors of Zhengzhou Antu Bioengineering Co., Ltd. It details the meeting attendance, voting results, and approval of several proposals including the use of idle raised funds and self-owned funds for cash management, and a change in securities affairs representative. The document does not contain financial statements or detailed financial data, but rather reports on board decisions and changes. It also references related independent opinions and verification opinions published separately. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board resolutions. The document length is short (1143 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-01-11 Chinese
安图生物关于变更证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's securities affairs representative, including details about the resignation of the previous representative and the appointment of a new one. It references compliance with stock exchange listing rules and provides contact information for the new representative. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG) as it relates to changes in company representatives and management roles.
2023-01-11 Chinese
安图生物关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle own funds for cash management. It details the investment purpose, amount, types of financial products, risk analysis, and board approval. The document is a formal disclosure about the company's financing activity related to cash management and investment of idle funds, not a financial report or earnings release. It does not contain financial statements or detailed financial results but rather an update on capital management decisions. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2512 characters, which is consistent with an announcement rather than a full report.
2023-01-11 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the board's approval of the share buyback plan, the price limits, the total amount authorized, and the actual shares repurchased to date, including prices and total amounts paid. The document references regulatory compliance with share repurchase rules and provides an update on the status of the buyback. It does not contain financial statements or detailed financial analysis but is a formal disclosure of share repurchase activity. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is short (1120 characters), and it is not merely an announcement of a report but the actual progress update on the repurchase. Therefore, the correct classification is POS with high confidence.
2023-01-03 Chinese
安图生物关于完成医疗器械经营许可证变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a change in the medical device business license registration for the company. It details the updated license information, addresses, and scope of business. There is no financial data, no mention of financial results, no shareholder voting, no management changes, and no regulatory certifications or legal proceedings. The document is a regulatory announcement about a license change, which does not fit into financial reports or other specific categories. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-12-30 Chinese
安图生物关于公司及子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the receipt of medical device registration certificates issued by the National Medical Products Administration and Henan Provincial Medical Products Administration. It details the registration certificates obtained for specific medical products, their intended uses, and validity periods. The document includes a risk warning and impact statement on the company's business but does not contain financial statements, management discussion, or detailed financial data. The document length is 1585 characters, which is relatively short and is clearly an announcement of a regulatory approval event rather than a financial report or detailed management report. There is no indication of it being a report publication announcement or a certification letter. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-12-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.